McCombe William D. reported option exercise involving 13,051 derivative units of Cytek Biosciences, Inc. at $0.00 for $0 on Aug 18, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Financial Officer
Chief Financial Officer
Filed Aug 20, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
13,051Restricted Stock Units
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
134,862Direct
Trade date
Aug 18, 2026Option exercise
Filed
Aug 20, 2026, 4:34 PM ET2-day reporting delay
Accession
0001878824-26-000004Code M · Transaction 13096
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Aug 18, 2026Tax withholding2,111$4.67−$9,858.37Trade 13090
Aug 18, 2026Tax withholding4,392$4.67−$20,510.64Trade 13092
Aug 18, 2026Tax withholding5,401$4.67−$25,222.67Trade 13094
Aug 18, 2026Option exercise6,320$0.00$0Trade 13095
Aug 18, 2026Option exercise16,049$0.00$0Trade 13097
Aug 18, 2026Option exercise6,320——Trade 13089
Aug 18, 2026Option exercise13,051——Trade 13091
Aug 18, 2026Option exercise16,049——Trade 13093
9 transaction rows in this filing. Joint filers share the same rows.

CTKB price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
CTKB · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −0.9%1w ago +1.7%1d ago +1.7%
Returns since7d −0.9%30d +14%90d180d1y

Footnotes in full

F1: Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock. F2: Represents the number of shares withheld by and surrendered to the Issuer on August 18, 2026 to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award. F3: The shares underlying the RSU Award shall vest over 4 years, with 12/48 of the total shares underlying the RSU Award vesting on May 18, 2025; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter; and 3/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter. F4: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter. F5: The shares underlying the RSU Award shall vest over 4 years, with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter.